Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Altman

Showing results (261-270 of 365) with videos related to

Pageof 37
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cellsNathalie Carayol, Eliza Vakana, Antonella Sassano, et al.
American Journal of Physiology. Endocrinology and Metabolism|September 11, 2008
Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female ratsJoshua F Yarrow, Christine F Conover, Amol V Purandare, et al.
Blood|June 10, 2011
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidJae H Park, Baozhen Qiao, Katherine S Panageas, et al.
Cancer Letters|August 31, 2015
Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cellsMolly K Altman, Ali A Alshamrani, Wei Jia, et al.
Cancer|November 18, 2022
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entityRory M Shallis, Naval G Daver, Jessica K Altman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2014
Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targetingJessica K Altman, Amy Szilard, Dennis J Goussetis, et al.
British Journal of Haematology|July 25, 2015
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxideDavid Sanford, Francesco Lo-Coco, Miguel A Sanz, et al.
Oncotarget|May 20, 2021
Inhibitory effects of Tomivosertib in acute myeloid leukemiaMilagros Suarez, Gavin T Blyth, Alain A Mina, et al.
Blood Advances|April 13, 2018
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with <i>FLT3</i>-ITD mutationsMark J Levis, Alexander E Perl, Jessica K Altman, et al.
Leukemia & Lymphoma|April 9, 2014
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomesOlga Frankfurt, Shuo Ma, Leo Gordon, et al.
Pageof 37

Showing results (261-270 of 365) with videos related to

Sort By:
Pageof 37
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cellsNathalie Carayol, Eliza Vakana, Antonella Sassano, et al.
American Journal of Physiology. Endocrinology and Metabolism|September 11, 2008
Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female ratsJoshua F Yarrow, Christine F Conover, Amol V Purandare, et al.
Blood|June 10, 2011
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidJae H Park, Baozhen Qiao, Katherine S Panageas, et al.
Cancer Letters|August 31, 2015
Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cellsMolly K Altman, Ali A Alshamrani, Wei Jia, et al.
Cancer|November 18, 2022
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entityRory M Shallis, Naval G Daver, Jessica K Altman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2014
Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targetingJessica K Altman, Amy Szilard, Dennis J Goussetis, et al.
British Journal of Haematology|July 25, 2015
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxideDavid Sanford, Francesco Lo-Coco, Miguel A Sanz, et al.
Oncotarget|May 20, 2021
Inhibitory effects of Tomivosertib in acute myeloid leukemiaMilagros Suarez, Gavin T Blyth, Alain A Mina, et al.
Blood Advances|April 13, 2018
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with <i>FLT3</i>-ITD mutationsMark J Levis, Alexander E Perl, Jessica K Altman, et al.
Leukemia & Lymphoma|April 9, 2014
Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomesOlga Frankfurt, Shuo Ma, Leo Gordon, et al.
Pageof 37